research

Our Mission is to develop the broadest range of clinical therapies with our breakthrough technology to benefit as many patients as possible suffering from metastatic bone cancer.

“Research never ceases at Zetagen because cancer never rests…”

We are appreciative to have the financial support of our investors and the National Institute of Health (NIH) through their variety of Small Business Innovation Research (SIBR) programs to support our research. Zetagen’s preclinical research is funded through a series of phase I and II grants from the National Cancer Institute (NCI) and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the NIH. 

ZetaMet™ was recently awarded a Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the treatment of metastatic bone cancer. Currently, ZetaMet™ is being reviewed by the FDA and Health Canada for a human clinical study for patients living with metastatic breast cancer. Enrollment for this study could begin late Q4-2021. Zetagen has several therapies in various stages of development.
research

COmpassionate

Use access

“Patients are at the center of everything that we do. Our goal is to provide breakthrough technologies to all patients that suffer from metastatic cancers providing relief and hope.” - Joe C. Loy

What IS compassionate Use?

Compassionate Use means making a new, unapproved therapy available to treat a seriously ill patient when other treatments have failed and no others are available.

Therapies that are being tested but have not yet been approved by the FDA are called investigational therapies. These therapies are normally available only to people who are taking part in a clinical trial.
The usual way to get treatment with an unapproved drug is through a clinical trial. But many people with life-threatening diseases can’t find clinical trials that they can be a part of. This could be because they live too far from locations where the studies are being conducted, or because they don’t meet the inclusion criteria.

If you have questions concerning Compassionate Use Access for any of Zetagen’s products, please contact us at compassionateuse@zetagen.com.